NZ701237A - Novel compounds and compositions for targeting cancer stem cells - Google Patents

Novel compounds and compositions for targeting cancer stem cells

Info

Publication number
NZ701237A
NZ701237A NZ701237A NZ70123711A NZ701237A NZ 701237 A NZ701237 A NZ 701237A NZ 701237 A NZ701237 A NZ 701237A NZ 70123711 A NZ70123711 A NZ 70123711A NZ 701237 A NZ701237 A NZ 701237A
Authority
NZ
New Zealand
Prior art keywords
compositions
stem cells
novel compounds
cancer stem
cancer
Prior art date
Application number
NZ701237A
Other languages
English (en)
Inventor
Chiang Jia Li
David Leggett
Wei Li
Youzhi Li
Original Assignee
Boston Biomedical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boston Biomedical Inc filed Critical Boston Biomedical Inc
Priority to NZ712826A priority Critical patent/NZ712826A/en
Priority claimed from NZ602328A external-priority patent/NZ602328A/en
Publication of NZ701237A publication Critical patent/NZ701237A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/92—Naphthofurans; Hydrogenated naphthofurans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
NZ701237A 2010-03-19 2011-03-21 Novel compounds and compositions for targeting cancer stem cells NZ701237A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
NZ712826A NZ712826A (en) 2010-03-19 2011-03-21 Novel compounds and compositions for targeting cancer stem cells

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US31588610P 2010-03-19 2010-03-19
US31589010P 2010-03-19 2010-03-19
US32581410P 2010-04-19 2010-04-19
NZ602328A NZ602328A (en) 2010-03-19 2011-03-21 Novel compounds and compositions for targeting cancer stem cells

Publications (1)

Publication Number Publication Date
NZ701237A true NZ701237A (en) 2016-04-29

Family

ID=50940329

Family Applications (2)

Application Number Title Priority Date Filing Date
NZ712826A NZ712826A (en) 2010-03-19 2011-03-21 Novel compounds and compositions for targeting cancer stem cells
NZ701237A NZ701237A (en) 2010-03-19 2011-03-21 Novel compounds and compositions for targeting cancer stem cells

Family Applications Before (1)

Application Number Title Priority Date Filing Date
NZ712826A NZ712826A (en) 2010-03-19 2011-03-21 Novel compounds and compositions for targeting cancer stem cells

Country Status (11)

Country Link
EP (2) EP3108750B1 (enExample)
JP (11) JP2014098050A (enExample)
CN (3) CN104016951B (enExample)
CA (3) CA2993363A1 (enExample)
DK (1) DK3108750T3 (enExample)
ES (1) ES2689928T3 (enExample)
HU (1) HUE066482T2 (enExample)
NZ (2) NZ712826A (enExample)
PT (1) PT2547205T (enExample)
RU (2) RU2015142279A (enExample)
SG (3) SG10201706265PA (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105963289B (zh) 2007-09-10 2021-02-26 北京强新生物科技有限公司 一类stat3通路抑制剂和癌干细胞通路抑制剂
RU2591823C2 (ru) * 2010-03-19 2016-07-20 Бостон Байомедикал, Инк. Новые способы направленного воздействия на раковые стволовые клетки
DK3108750T3 (en) * 2010-03-19 2018-10-22 1Globe Biomedical Co Ltd NEW RELATIONS AND COMPOSITIONS TARGETED FOR CANCER STAM CELLS
SG11201508358RA (en) 2013-04-09 2015-11-27 Boston Biomedical Inc 2-acetylnaphtho[2,3-b]furan -4,9-dione for use on treating cancer
MX2017015618A (es) * 2015-06-03 2018-08-15 Boston Biomedical Inc Composiciones que comprenden un inhibidor de la autorrenovación y diferenciación de células madre cancerosas y un agente inmunoterapéutico para su uso en el tratamiento del cáncer.
GB201515391D0 (en) * 2015-08-28 2015-10-14 Amazentis Sa Compositions
GB201515387D0 (en) * 2015-08-28 2015-10-14 Amazentis Sa Compositions
JP6751658B2 (ja) 2016-11-15 2020-09-09 クラリオン株式会社 音声認識装置、音声認識システム
JP7106563B2 (ja) 2016-11-29 2022-07-26 スミトモ ファーマ オンコロジー， インコーポレイテッド ナフトフラン誘導体、その調製、および使用方法
WO2018213424A1 (en) 2017-05-17 2018-11-22 Boston Biomedical, Inc. Methods for treating cancer

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61205257A (ja) * 1985-03-08 1986-09-11 Ishihara Sangyo Kaisha Ltd ベンゾイルウレア系化合物、その製法及びそれを含有する抗ガン剤
EP0945131A1 (de) * 1998-03-27 1999-09-29 Boehringer Ingelheim Pharma KG Perorale Wirkstoff-Suspension
WO2000044774A2 (en) * 1999-01-27 2000-08-03 The University Of South Florida Inhibition of stat3 signal transduction for human cancer therapy
AU2003275056A1 (en) * 2002-09-17 2004-04-08 Arqule, Inc. Novel lapacho compounds and methods of use thereof
AR042052A1 (es) * 2002-11-15 2005-06-08 Vertex Pharma Diaminotriazoles utiles como inhibidores de proteinquinasas
WO2006087919A1 (ja) * 2005-01-28 2006-08-24 Takeda Pharmaceutical Company Limited 難水溶性物質含有微細化組成物
JP2006290871A (ja) * 2005-03-16 2006-10-26 Taheebo Japan Kk 抗癌性を示す化合物およびその中間体ならびにそれらの製造方法
EP1940358A2 (en) * 2005-09-30 2008-07-09 SmithKline Beecham Corporation Pharmaceutical compositions
EP1860126A1 (en) * 2006-05-26 2007-11-28 INEOS Manufacturing Belgium NV Polyolefin powder
CN105963289B (zh) 2007-09-10 2021-02-26 北京强新生物科技有限公司 一类stat3通路抑制剂和癌干细胞通路抑制剂
NZ590334A (en) * 2008-07-08 2012-12-21 Beta Pharma Inc ICOTINIB HYDROCHLORIDE (4-[(3-ethynylphenyl)amino]-6,7-benzo-12-crownquinazoline hydrochloride), SYNTHESIS, CRYSTALLOGRAPHIC FORM, MEDICAL COMBINATION, AND USES THEREOF
ES2659541T3 (es) * 2010-03-19 2018-03-16 1Globe Biomedical Co., Ltd. Compuestos y composiciones novedosas para direccionar hacia células madre del cáncer
DK3108750T3 (en) * 2010-03-19 2018-10-22 1Globe Biomedical Co Ltd NEW RELATIONS AND COMPOSITIONS TARGETED FOR CANCER STAM CELLS
RU2591823C2 (ru) * 2010-03-19 2016-07-20 Бостон Байомедикал, Инк. Новые способы направленного воздействия на раковые стволовые клетки

Also Published As

Publication number Publication date
NZ712826A (en) 2017-03-31
ES2689928T3 (es) 2018-11-16
JP2014098050A (ja) 2014-05-29
JP5993390B2 (ja) 2016-09-14
JP2018002744A (ja) 2018-01-11
JP2014098048A (ja) 2014-05-29
JP2015098489A (ja) 2015-05-28
JP2014098049A (ja) 2014-05-29
CN106860443A (zh) 2017-06-20
HUE066482T2 (hu) 2024-08-28
JP2022020002A (ja) 2022-01-27
EP3295796A1 (en) 2018-03-21
SG10201502079VA (en) 2015-06-29
JP2020063308A (ja) 2020-04-23
SG10201706265PA (en) 2017-08-30
JP2016222723A (ja) 2016-12-28
RU2015142279A3 (enExample) 2019-02-26
RU2657750C1 (ru) 2018-06-15
JP2015232037A (ja) 2015-12-24
CA2959951A1 (en) 2011-09-22
JP6246169B2 (ja) 2017-12-13
CN107311969B (zh) 2022-01-28
JP2018115209A (ja) 2018-07-26
CN104016951B (zh) 2016-07-13
PT2547205T (pt) 2024-05-27
JP2020114888A (ja) 2020-07-30
CA2959931A1 (en) 2011-09-22
SG10201704745UA (en) 2017-07-28
CA2993363A1 (en) 2011-09-22
EP3108750A1 (en) 2016-12-28
CN107311969A (zh) 2017-11-03
DK3108750T3 (en) 2018-10-22
EP3108750B1 (en) 2018-07-04
CN104016951A (zh) 2014-09-03
RU2015142279A (ru) 2018-12-28

Similar Documents

Publication Publication Date Title
NZ701237A (en) Novel compounds and compositions for targeting cancer stem cells
NZ602328A (en) Novel compounds and compositions for targeting cancer stem cells
IN2012DN03182A (enExample)
IN2014DN09805A (enExample)
WO2011042918A3 (en) Improved processes for preparing prasugrel and pharmaceutically acceptable salts thereof
MY148583A (en) Pyridine [3,4-b] pyrazinones
WO2012015681A3 (en) Drug-ligand conjugates, synthesis thereof, and intermediates thereto
WO2014045162A8 (en) ALKYL-SUBSTITUTED HEXAHYDROPYRANO[3,4-d] [1,3]THIAZIN-2-AMINE COMPOUNDS
WO2009091898A3 (en) 6-and 7-amino isoquinoline compounds and methods for making and using the same
TN2012000248A1 (en) Novel spiropiperidine compounds
MX338551B (es) Nuevos compuestos de piridina fusionada como inhibidores de caseina quinasa.
PH12015500376A1 (en) Novel bicyclic pyridinones
WO2011009938A3 (en) Stambomycin and derivatives, their production and their use as drugs
MX2013000474A (es) Derivados de arilamida novedosos que tienen propiedades antiandrogenicas.
WO2010150211A3 (en) Use of derivatives of indoles for the treatment of cancer
NZ602578A (en) Polymorphic forms st-246 and methods of preparation
WO2013040227A3 (en) Therapeutic compounds
MX2013013465A (es) Polimorfo de rifaximina y proceso para la preparacion del mismo.
MX2012002369A (es) Formas de anhidrato de un derivado de piridina.
CA2817362C (en) Lipoyl compounds and their use for treating ischemic injury
WO2011021864A3 (ko) 신규한 항암제 보조용 화합물, 이의 제조방법, 이를 포함하는 항암제 보조용 조성물 및 이를 이용한 항암제에 대한 내성을 감소시키는 방법
PH12012502323A1 (en) Levoisovalerylspiramycin i, ii or iii, preparations, preparation methods and uses thereof
WO2012135615A3 (en) Enopeptins, uses thereof, and methods of synthesis thereto
WO2010049449A3 (en) Novel salts of sunitinib
WO2013042135A8 (en) Heteroaryl compounds as 5-ht4 receptor ligands

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 21 MAR 2018 BY CULLENS PTY LTD

Effective date: 20160811

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 21 MAR 2019 BY JING LEI

Effective date: 20180309

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 21 MAR 2020 BY JING LEI

Effective date: 20190226

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 21 MAR 2021 BY JING LEI

Effective date: 20200217

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 21 MAR 2022 BY JING LEI

Effective date: 20210308

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 21 MAR 2023 BY PAVIS PAYMENT GMBH

Effective date: 20220412

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 21 MAR 2024 BY JING LEI

Effective date: 20230313

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 21 MAR 2025 BY JING LEI

Effective date: 20240313

LAPS Patent lapsed